These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 20847160)

  • 1. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model.
    Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ
    J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.
    McKinley ET; Smith RA; Zhao P; Fu A; Saleh SA; Uddin MI; Washington MK; Coffey RJ; Manning HC
    J Nucl Med; 2013 Mar; 54(3):424-30. PubMed ID: 23341544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorine-18-Labeled Thymidine Positron Emission Tomography (FLT-PET) as an Index of Cell Proliferation after Pharmacological Ascorbate-Based Therapy.
    Cieslak JA; Sibenaller ZA; Walsh SA; Ponto LL; Du J; Sunderland JJ; Cullen JJ
    Radiat Res; 2016 Jan; 185(1):31-8. PubMed ID: 26720803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voxel-Based Analysis of the Relation of 3'-Deoxy-3'-[
    Schelhaas S; Frohwein LJ; Wachsmuth L; Hermann S; Faber C; Schäfers KP; Jacobs AH
    Mol Imaging Biol; 2022 Jun; 24(3):359-364. PubMed ID: 34755247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Applications of 3'-Deoxy-3'-[
    Schelhaas S; Heinzmann K; Bollineni VR; Kramer GM; Liu Y; Waterton JC; Aboagye EO; Shields AF; Soloviev D; Jacobs AH
    Theranostics; 2017; 7(1):40-50. PubMed ID: 28042315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET imaging of early response to the tyrosine kinase inhibitor ZD4190.
    Yang M; Gao H; Yan Y; Sun X; Chen K; Quan Q; Lang L; Kiesewetter D; Niu G; Chen X
    Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1237-47. PubMed ID: 21360246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High efficacy of particle beam therapies against tumors under hypoxia and prediction of the early stage treatment effect using 3'-deoxy-3'-[
    Makino A; Kume K; Mori T; Tsujikawa T; Asai T; Okazawa H; Kiyono Y
    Ann Nucl Med; 2024 Feb; 38(2):112-119. PubMed ID: 37856073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proliferation and apoptosis after whole-body irradiation: longitudinal PET study in a mouse model.
    Meindl M; Bläske A; Steiger K; Lindner S; Lindheimer F; Lauber K; Brix N; von Ungern-Sternberg B; Oos R; Palumbo G; Böning G; Schüle S; Majewski M; Port M; Ziegler S; Bartenstein P
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):395-404. PubMed ID: 37796306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma.
    Huynh H; Ng WH; Soo KC
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline and on Treatment Biodistribution Variability of 18 F-FLT Uptake in Patients With Advanced Melanoma: Brief Communication.
    van der Hiel B; Aalbersberg EA; van den Eertwegh AJM; Fischer J; Boellaard R; de Vos FYFL; Boers-Sonderen MJ; Stokkel MPM; de Wit-van der Veen LJ; Haanen JBAG
    Clin Nucl Med; 2024 Aug; 49(8):722-726. PubMed ID: 38768063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B-cell lymphoma.
    Lee SC; Marzec M; Liu X; Wehrli S; Kantekure K; Ragunath PN; Nelson DS; Delikatny EJ; Glickson JD; Wasik MA
    NMR Biomed; 2013 Jan; 26(1):106-14. PubMed ID: 22711601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammalian target of rapamycin inhibition impacts energy homeostasis and induces sex-specific body weight loss in humans.
    Mannaa M; Pfennigwerth P; Fielitz J; Gollasch M; Boschmann M
    J Cachexia Sarcopenia Muscle; 2023 Dec; 14(6):2757-2767. PubMed ID: 37897143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tunneling nanotube formation is stimulated by hypoxia in ovarian cancer cells.
    Desir S; Dickson EL; Vogel RI; Thayanithy V; Wong P; Teoh D; Geller MA; Steer CJ; Subramanian S; Lou E
    Oncotarget; 2016 Jul; 7(28):43150-43161. PubMed ID: 27223082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between endogenous thymidine concentrations and [(18)F]FLT uptake in a range of preclinical tumour models.
    Heinzmann K; Honess DJ; Lewis DY; Smith DM; Cawthorne C; Keen H; Heskamp S; Schelhaas S; Witney TH; Soloviev D; Williams KJ; Jacobs AH; Aboagye EO; Griffiths JR; Brindle KM
    EJNMMI Res; 2016 Dec; 6(1):63. PubMed ID: 27515446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo detection of poststroke cerebral cell proliferation in rodents and humans.
    Chiang PT; Tsai HH; Yen RF; Tsai YC; Wu CH; Chiu CH; Tsai LK
    Ann Clin Transl Neurol; 2024 Feb; 11(2):497-507. PubMed ID: 38115693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic Anti-Tumor Activity by Targeting Multiple Signaling Pathways in Ovarian Cancer.
    Wen W; Han ES; Dellinger TH; Lu LX; Wu J; Jove R; Yim JH
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32927828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals.
    O'Reilly T; McSheehy PM
    Transl Oncol; 2010 Apr; 3(2):65-79. PubMed ID: 20360931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upfront treatment with mTOR inhibitor everolimus in pediatric low-grade gliomas: A single-center experience.
    Cacchione A; Lodi M; Carai A; Miele E; Tartaglia M; Megaro G; Del Baldo G; Alessi I; Colafati GS; Carboni A; Boccuto L; Diomedi Camassei F; Catanzaro G; Po A; Ferretti E; Pedace L; Pizzi S; Folgiero V; Pezzullo M; Corsetti T; Secco DE; Cefalo MG; Locatelli F; Mastronuzzi A
    Int J Cancer; 2021 May; 148(10):2522-2534. PubMed ID: 33320972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Patient Tissueoid with Self-Homing Nano-Targeting of Metabolic Inhibitor.
    Yoon HJ; Chung YS; Lee YJ; Yu SE; Baek S; Kim HS; Kim SW; Lee JY; Kim S; Sung HJ
    Adv Sci (Weinh); 2021 Nov; 8(22):e2102640. PubMed ID: 34664430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of mTOR pathway as target for treatment in adrenocortical cancer.
    De Martino MC; Feelders RA; Pivonello C; Simeoli C; Papa F; Colao A; Pivonello R; Hofland LJ
    Endocr Connect; 2019 Sep; 8(9):R144-R156. PubMed ID: 31398711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.